Latest / The Operator's Manual with Fexingo: Daily Decisions, Tactical Wins, and Business Execution / How a Single Plant Delay Shook the Global Pharma Supply Chain
Transcript
- Lucas: So there's a moment in early 2025 that most people outside pharma never heard about. A Pfizer plant in Kalamazoo, Michigan — one of their older sites, built in the 1960s — had a contamination event on a single filling line for a generic chemotherapy drug called cisplatin. Luna: Cisplatin — that's one of the most common treatments for testicular, ovarian, lung cancers. It's been around for decades. Lucas: Exactly. And because it's off-patent, margins are thin. There are only a handful of suppliers globally. Pfizer was one of maybe four US manufacturers. When that line went down, the entire market felt it. Luna: How bad was the contamination? Lucas: Not a full plant shutdown. Just one filling line — but that line accounted for roughly 15 percent of the total US supply of cisplatin. The contamination was found during routine sterility testing. The plant manager had to quarantine 500,000 vials. That's about six weeks of production. Luna: Six weeks of production sitting in quarantine. Meanwhile, hospitals are ordering this stuff every week. Lucas: Right. And the backup plan — other suppliers — couldn't ramp fast enough. The other US manufacturer, a smaller company called Sagent, was already running at near capacity. So within two weeks, the FDA had to authorize a temporary import from a plant in India, which is rare for a sterile injectable. Luna: That's a huge operational step. Normally the FDA takes months to approve foreign imports for generics. They did it in days. Lucas: Days. But here's the thing — the Indian supplier, Cipla, had its own quality concerns. They'd had Form 483s in the past. So the FDA had to weigh the risk of a known substitute against the risk of no drug at all. Luna: And they chose the import. Which tells you how serious the shortage was. Lucas: Yeah. And this is the operational lesson: when you run a lean supply chain in a high-stakes industry, a single line failure cascades faster than anyone models. Pfizer had redundancy on paper — they had two lines. But one was down for maintenance, and the other got contaminated. Luna: So they had zero redundancy at that moment. And the market had no buffer. Lucas: That's the part that surprised me when I looked into it. The average inventory of cisplatin at hospitals is about 14 days. The quarantine alone was six weeks of production. Once that buffer ran out, you had a national shortage for a drug that has no substitute. Luna: No therapeutic alternative. If you're a patient needing cisplatin, you can't just switch to another drug. So this is a life or death operations failure. Lucas: Absolutely. And the interesting operational question is: why didn't the system absorb this? Because we've known about pharma supply chain fragility since the 2011 Fukushima disaster, which caused a shortage of contrast dye for CT scans. Luna: Right, that was a classic single point of failure lesson. And yet here we are, 14 years later, with the same vulnerability. Lucas: The answer is economics. Cisplatin sells for about 15 dollars per vial. The margin is razor thin. Building redundant capacity — extra lines that sit idle most of the time — costs millions. No company wants to invest in capacity that only gets used during someone else's crisis. Luna: So the market doesn't pay for resilience. That's a classic public goods problem. Lucas: Exactly. And the FDA has been trying to address it with voluntary quality ratings and incentive programs. But none of that would have prevented the Kalamazoo contamination. The root cause was a small tear in a stainless steel tank that held the sterile solution. It was a maintenance issue. Luna: A tear. So not a systemic quality failure, just an equipment failure that any plant can have. Lucas: Right. And that's what makes it so hard to plan for. You can't model every possible equipment failure. But you can build in buffers. The best operational hedge is inventory. The US government actually stockpiles some drugs through the Strategic National Stockpile, but cisplatin wasn't on the list. Luna: Why not? It's a cancer drug used by thousands of patients every month. Lucas: The stockpile focuses on emergencies — anthrax, chemical attacks, pandemic flu. Chronic-use cancer drugs are considered the responsibility of the commercial market. But as we saw, the commercial market has no incentive to hold 90 days of inventory. That's 13 million dollars sitting in a warehouse. Luna: So the policy gap is clear. But operationally, what could Pfizer have done differently? Lucas: They could have maintained a third line. Or they could have dual-sourced the drug across two different plants. But again, that's expensive. The profit on cisplatin is so low that if they ran two lines, the product might not be profitable at all. Luna: So the system is structurally fragile because the economics don't support resilience. That feels like a design flaw. Lucas: It is. And the fix probably has to come from regulation. Some proposals suggest requiring generic drug makers to hold a minimum of six months of inventory, or pay a penalty if they cause a shortage. But that would raise prices. Luna: And then the same people who want low drug prices would complain. It's a trade-off. Lucas: Exactly. So the Kalamazoo case is a perfect illustration of a classic operations tension: efficiency versus resilience. The industry optimized for low cost and just-in-time delivery. And it works — until it doesn't. Luna: What happened after the import from India? Did the shortage resolve? Lucas: Eventually. The Cipla import covered about 30 percent of the gap. Then Pfizer fixed the line after about eight weeks. But for about a month, hospitals were rationing cisplatin. Some patients had their doses delayed by a week or two. Luna: And that's the real cost. Not measured in dollars, but in treatment delays. Lucas: Right. And that's why this matters for any operations person — whether you're in pharma or not. The lesson is: identify your single points of failure, and ask whether the cost of a buffer is worth the risk of a shutdown. Most companies don't do that math until it's too late. Luna: It reminds me of something we talked about in the Target episode — the inventory mistake that cost them 20 billion. Different industry, same failure mode. Lucas: Exactly. And you know, a handful of listeners help keep this show going through buy me a coffee dot com slash fexingo. That support lets us keep drilling into these cases without running ads. So if you've gotten something useful from episodes like this one, that's how you can make sure more of them get made. Luna: Yeah, it genuinely helps us spend the time on the research. And we appreciate it. Lucas: So back to the pharma angle — one thing I find striking is how little visibility hospitals have into their suppliers' operations. When the shortage hit, many hospitals didn't know how much cisplatin they had on hand. They had to manually count vials. Luna: That's a data problem. If they had real-time inventory visibility, they could have redistributed stock earlier. Lucas: Exactly. And some hospitals are now investing in RFID tracking for high-risk drugs. But it's slow. The whole system moves at the speed of regulation and budget cycles. Luna: So the takeaway for listeners in any industry — find your single-source drug, or part, or component. And ask: what happens if that line goes down for six weeks? Lucas: And if the answer is 'we have no backup,' then you have a decision to make. Because the market won't save you. The FDA can't save you fast enough. It's on you.